Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2768 Carcinoma, Non-Small-Cell Lung 2267 Prostatic Neoplasms 1427 Colorectal Neoplasms 1295 Neoplasms 1260 Multiple Myeloma 1086 Lung Neoplasms 1050 Neoplasm Metastasis 995 Leukemia, Myeloid, Acute 985 Lymphoma 900 Melanoma 864 Pancreatic Neoplasms 819 Ovarian Neoplasms 805 Carcinoma, Hepatocellular 782 Stomach Neoplasms 754 Recurrence 753 Leukemia 733 Lymphoma, Non-Hodgkin 685 Leukemia, Lymphocytic, Chronic, B-Cell 665 Squamous Cell Carcinoma of Head and Neck 618 Lymphoma, Large B-Cell, Diffuse 617 Precursor Cell Lymphoblastic Leukemia-Lymphoma 605 Head and Neck Neoplasms 599 Brain Neoplasms 593 Carcinoma, Renal Cell 587 Glioblastoma 573 Rectal Neoplasms 565 Sarcoma 523 Myelodysplastic Syndromes 522 Lymphoma, Follicular 516

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interventional × Rare Tumour × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡